Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 1/20 | 0.43 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8625804 | 0.83 | GABRP (0.46) | P2RX3P2RX2HSP90AA1KDM4EALDH1A1 | |
| SCHEMBL27415510 | 0.81 | HSP90AA1 (0.41) | P2RX3P2RX2HSP90AA1KDM4E | |
| SCHEMBL14757636 | 0.81 | NNMT (0.46) | P2RX3P2RX2HSP90AA1KDM4EHPGD | |
| SCHEMBL16649308 | 0.81 | HSP90AA1 (0.38) | P2RX3P2RX2HSP90AA1KDM4EALDH1A1 | |
| SCHEMBL14619795 | 0.79 | IKBKB (0.41) | IKBKBKDM4EALDH1A1GLAGAA | |
| SCHEMBL584137 | 0.79 | NNMT (0.43) | IKBKBKDM4EALDH1A1GLAGAA | |
| SCHEMBL16120968 | 0.79 | CSNK1A1 (0.44) | IKBKBKDM4EALDH1A1GLAGAA | |
| SCHEMBL11255807 | 0.78 | DHFR (0.33) | — | |
| SCHEMBL30468126 | 0.76 | TSHR (0.47) | HSP90AA1KDM4EALDH1A1GLAGAA | |
| SCHEMBL6527376 | 0.76 | MAPK8 (0.42) | IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105753798-A | Novel gas production compound | 北京理工大学 | 2016-07-13 | — | — | CN | claimed |
| EP-4655302-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | The University of North Carolina at Chapel Hill (US) | 2025-12-03 | — | — | EP | disclosed |
| WO-2024159097-A1 | TYRO3 SELECTIVE INHIBITORS AND USES THEREOF | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-08-02 | — | — | WO | disclosed |
| EP-3600440-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | Sienna Biopharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| WO-2020023389-A1 | REDUCED EXPOSURE COMPOSITIONS MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2020-01-30 | — | — | WO | disclosed |
| WO-2019057112-A1 | 2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2019-03-28 | — | — | WO | disclosed |
| WO-2018175340-A1 | REDUCED EXPOSURE CONJUGATES MODULATING THERAPEUTIC TARGETS | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| WO-2018175315-A1 | POLYMER CONJUGATES OF STAUROSPORINE DERIVATIVES HAVING REDUCED EXPOSURE | SIENNA BIOPHARMACEUTICALS, INC. (US) | 2018-09-27 | — | — | WO | disclosed |
| CN-105753798-A | Novel gas production compound | 北京理工大学 | 2016-07-13 | — | — | CN | disclosed |
| CN-105753798-A | Novel gas production compound | 北京理工大学 | 2016-07-13 | — | — | CN | disclosed |
| CN-102066339-A | 2, 6-diamino-pyrimidin-5-yl-carboxamides as SYK or JAK protein kinase inhibitors | PORTOLA PHARM INC | 2011-05-18 | — | — | CN | disclosed |
| CN-102066340-A | 2, 6-diamino-pyrimidin- 5-yl-carboxamides as SRK or JAK kinases inhibitors | PORTOLA PHARM INC | 2011-05-18 | — | — | CN | disclosed |
| JP-2010174027-A | DIAMINOPYRIMIDINE CARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC | 2010-08-12 | — | — | JP | disclosed |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | ASTELLAS PHARM INC. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-7449456-B2 | Diaminopyrimidinecarboxamide derivative | ASTELLAS PHARMA, INC. (JP) | 2008-11-11 | — | — | US | disclosed |
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | ASTELLAS PHARMA INC. (JP) | 2005-12-08 | — | — | US | disclosed |
| CN-1665789-A | Diaminopyrimidinecarboxa mide derivative | YAMANOUCHI PHARMA CO LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-1518855-A1 | DIAMINOPYRIMIDINECARBOXA MIDE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-RE31136-E | Herbicidal 5-pyrimidinecarbonitriles | FMC CORPORATION (US) | 1983-02-01 | — | — | US | disclosed |
| US-4092150-A | Herbicidal 5-pyrimidinecarbonitriles | FMC CORPORATION (US) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272753-A1 | Diaminopyrimidinecarboxa mide derivative | STAT5A, STAT6, STAT4 | P2RX3 3278/4885P2RX2 3799/4885IKBKB 95/4885 |
| US-20090281072-A1 | Diaminopyrimidinecarboxamide Derivative | STAT6, STAT4, STAT3 | P2RX3 2969/4885P2RX2 3201/4885IKBKB 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.